drugset / Trial / NCT00195260
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
Timeline
- Start
- 2004-10
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 50 mg | — |
| Subject | Bosutinib | Small molecule | 100 mg | — |
| Subject | Bosutinib | Small molecule | 200 mg | — |
| Subject | Bosutinib | Small molecule | 300 mg | — |
| Subject | Bosutinib | Small molecule | 400 mg | — |
| Subject | Bosutinib | Small molecule | 500 mg | — |
| Subject | Bosutinib | Small molecule | 600 mg | — |